Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: Post-marketing surveillance results
Norio Hanafusa(Nihon University), Michio Kato, Atsushi Arakawa(Nagoya City University), Ken Ishitani(Kitasato Institute Hospital), Toshihiko Yamaka(Kanagawa Institute of Technology), Hirokazu Onodera(Asahi Kasei (Japan)), Taihei Kashiwabara(Asahi Kasei (Japan)), Toyoko Numata(Asahi Kasei (Japan)), Ayako Isoai(Asahi Kasei (Japan)), Naoko Torii(Asahi Kasei (Japan)), Yoshihiro Matsuno(Hokkaido University Hospital), Tetsuya Ito(Japanese Red Cross Medical Center), Ryosuke Kobayashi(Asahi Kasei (Japan)), Tetsuya Inoue(Tokyo University of Science), Tomoaki Ishihara(RIKEN), Yasuo Itano(Iwaki Kyoritsu General Hospital), Taiju Utsugisawa(Tokyo Women's Medical University), Yosuke Yamada(Shinshu University Hospital)
Cited by 56
Related Papers
An Overview of Regular Dialysis Treatment in Japan (As of 31 December 2013)
|Therapeutic Apheresis and Dialysis|2015|425
Overview of Regular Dialysis Treatment in Japan (as of 31 December 2008)
|Therapeutic Apheresis and Dialysis|2010|228
Overview of Regular Dialysis Treatment in <scp>J</scp>apan (as of 31 <scp>D</scp>ecember 2011)
|Therapeutic Apheresis and Dialysis|2013|198
Annual dialysis data report for 2018, JSDT Renal Data Registry: survey methods, facility data, incidence, prevalence, and mortality
|Renal Replacement Therapy|2020|170